In a research report issued today, Piper Jaffray analyst Joshua Schimmer offered some positive commentary on bluebird bio Inc (NASDAQ:BLUE). The analyst reiterated an …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on bluebird bio Inc (NASDAQ:BLUE) Monday, reiterating a Buy rating and price target …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies Inc (NASDAQ:AAVL) blew up spectacularly …
This weekend, bluebird bio Inc (NASDAQ:BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) …
Piper Jaffray analyst Joshua Schimmer came out with a research report on bluebird bio Inc (NASDAQ:BLUE) following an EHA conference where data was presented about HGB-205 which could …
Micron Technology, Inc. (NASDAQ:MU) shares fell -3.
